

March 5, 2021 | Issue 162

Editor's note

This note is produced every Friday by the KPMG Center for Healthcare Regulatory Insight and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to subscribe to our mailing list here.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> here to me, Larry Kocot, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.



Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized COVID-19 news for the week in this special supplement.





Healthcare regulatory news

206,236 individuals <u>signed up for ACA special enrollment period coverage</u> in the first two weeks, <u>nearly three times</u> enrollment for the same period in 2020.

Elizabeth Fowler <u>was named CMMI Director</u>... CMMI is <u>reviewing the Geographic Direct Contracting</u> model.

FDA released a Data Modernization Action Plan.

GAO reported that <u>hospitals used some Medicare Part B drugs</u> more when eligible for pass-through payments... GAO <u>added prevention, response, and recovery from drug misuse</u> to its High Risk List... GAO <u>warned of an impending FDA foreign inspections backlog.</u>





Healthcare law and policy news

Senate Finance Committee <u>advanced (14-14 party line vote)</u> Xavier Becerra's nomination as HHS Secretary.

The House <u>passed (219-212) the \$1.9T</u> COVID-19 relief package; the Senate began debate on its version.

A district court <u>upheld AstraZeneca's Symbicort patents</u>, delaying <u>Mylan competition</u>... A BCBS Minnesota <u>class-action suit alleges Vyera Pharmaceuticals</u> monopolized the market for Daraprim.

DARPA <u>awarded GE and collaborators \$14M</u> to scale next generation RNA/DNA-based vaccines... Verily will <u>collaborate with Highmark on its Living Health model</u>... 98point6 will partner with Quest Diagnostics <u>to deliver text-based primary care</u> following employer health screenings... Care Medical, Amazon Care's clinical provider, <u>plans to operate</u> in 17 additional states... Provider groups formed <u>the Moving Health Home Coalition</u> to <u>advance permanent home healthcare reimbursement</u> changes.

FTC dropped its opposition to the Jefferson Health-Albert Einstein merger... Insight will acquire Mercy hospital... Amgen will acquire Five Prime Therapeutics (\$1.9B)... Merck will pay \$1.08B to develop/commercialize a Debiopharm head/neck cancer treatment... Perrigo will sell its generic drug business to Altaris Capital Partners (\$1.55B)... Highmark and HealthNow New York completed their affiliation.

Medicare physician <u>spending declined \$9.4B (19%)</u> in the first half of 2020... KFF estimated that reimbursing providers at Medicare rates would reduce <u>private insurance healthcare spending \$352B (41%) in 2021...</u> FAIR Health reported that <u>telehealth medical claims increased 2,937% nationally</u> November 2019-November 2020.

Health Affairs studies found: an average annual 128% turnover rate for nursing staff in nursing homes; ACA subsidies were associated with 17% lower out-of-pocket spending for low-income adults; rural residents are more than twice as likely as urban residents to switch from Medicare Advantage to traditional Medicare; and that 30-day episode payments reduced costs for three surgeries by \$4,229 (10.7%).





Questions or comments, please send to ushcinsight@kpmg.com.

Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.



kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 by the Numbers

There are now over 28.8 million confirmed COVID-19 cases in the US, with a <u>death toll over 520,000</u>... The United States averaged <u>just under 65,000 cases per day over the past week</u>, unchanged from last week, although testing rates continue to decline and concerns are increasing of a potential "fourth wave."

CDC Director Rochelle Walensky warned <u>about a "very concerning" recent increase</u> in COVID-19 cases and warned states that <u>"now is not the time"</u> to lift public health restrictions... The governors of Texas and Mississippi <u>issued executive orders to lift state mask mandates</u> and permit all businesses to reopen at full capacity.

82.6 million COVID-19 vaccine doses have been administered in the US (2.04M/day over the last week).

The World Health Organization's Health Emergencies Programme Director said it was "premature" and "unrealistic" to believe the pandemic could be over by the end of 2021.

Executive and Administrative Action

CDC delayed release of guidance for Americans who have already been fully vaccinated.

STAT reported that the Trump Administration spent roughly \$10 billion intended for hospital and provider relief on Operation Warp Speed contracts.

Education Secretary Miguel Cardona released a <u>five-point plan for resuming full-time, in-person schools,</u> including convening a national summit this month on how to safely reopen schools.

Healthcare Regulatory News

CMS <u>guidance</u> stated that COVID-19 testing and vaccines must be available to all health plan enrollees without cost-sharing and that insurers <u>cannot deny test coverage to individuals who are asymptomatic</u> or have no known exposure.

FDA granted <u>emergency use authorization for Quidel's</u> prescription at-home COVID-19 rapid antigen test and <u>Abbott's COVID-19 antibodies test</u>.

FDA warned about improper use of thermal imaging devices to screen for COVID-19 infection.

Healthcare Law, Business, and Policy News

A JAMA study concluded that <u>electronic medical records can be effective</u> for identifying people at risk of COVID-19 infection due to sharing a household with a PCR-confirmed COVID-19 patient... A FAIR Health analysis showed that the pandemic drove a roughly <u>doubling in demand for mental healthcare for children 13-18</u> in March and April 2020, compared to 2019.

Scientists have applied for <u>a patent for an RNA-based vaccine for malaria</u> that builds on COVID-19 vaccine technology.

The Senate began work to pass the American Rescue Act... President Biden and Senate Democrats agreed to phase out \$1,400 stimulus checks for individuals based on a lower income threshold... The Senate bill would also delay until 2024 removal of the cap on Medicaid drug inflation rebates; add \$8.5 billion for rural healthcare providers; increase Medicare reimbursement payments for hospitals in three urban states (NJ, RI, DE) and ambulances that care for patients at home or another site; and increase COBRA subsidies in the bill to 100%, up from 85% in the House bill.

World Health Organization investigators <u>will not release an interim report</u> on its mission to China to determine the origins of COVID-19 following ongoing concerns about the investigation's thoroughness and transparency.

Surveillance, Testing, and Treatment

Following a <u>unanimous recommendation</u> from the CDC Advisory Committee on Immunization Practices (ACIP), FDA <u>granted emergency use authorization</u> for Johnson & Johnson's (J&J) single-dose COVID-19 vaccine... J&J is <u>developing a booster vaccine</u> to protect against emerging virus strains... J&J stated that it <u>intended to unblind its vaccine trial</u> once granted EUA, providing vaccines to individuals in the placebo group... Merck will <u>help support manufacturing</u> of J&J's vaccine.

The Biden Administration will begin allocating 15.2 million Pfizer and Moderna COVID-19 vaccine doses to states, tribes, and territories each week, up from 14.5 million, along with 2.8 million J&J doses... President Biden said that there would be enough COVID-19 vaccines available for all US adults by the end of May... President Biden plans to use federal authority to provide at least one dose of a COVID-19 vaccine to all K-12 teachers and child care workers by the end of March... the Administration announced a new initiative with health insurers to fully vaccinate 2 million people 65 and older from vulnerable communities over the next 100 days... NIAID Director Anthony Fauci said elementary school-aged children will likely have access to COVID-19 vaccines in early 2022.

CDC's ACIP considered whether people who have recovered from COVID-19 <u>only need a single dose of Pfizer or Moderna's vaccine</u> under the assumption that the previous infection "primes" the body's immune response.

Novavax CEO said its experimental COVID-19 vaccine <u>could be authorized by the FDA as soon as May if the agency</u> permits it to use data from its British trial; 110 million doses could be delivered to the US government by July... Novavax <u>signed an exclusive license agreement</u> for Takeda's COVID-19 vaccine candidate; Takeda began a phase 1/2 trial in Japan.

Novartis will <u>help manufacture a COVID-19 vaccine</u> candidate from CureVac.

A *New England Journal of Medicine* study detailed delayed rashes experienced by some individuals who receive the Moderna COVID-19 vaccine.

NIH stopped a clinical trial of COVID-19 convalescent plasma to treat patients with mild to moderate symptoms after an analysis showed it provided no benefit to the group... NIH <u>launched a research program</u> to examine why some children face greater risk of COVID-19 infection and symptoms than others... NIH issued a <u>contract to test existing antivirals</u> against COVID-19 in a high-level biocontainment lab... Merck will <u>launch a clinical trial</u> of an experimental COVID-19 therapeutic acquired from Oncolmmune in November... GlaxoSmithKline and Vir Biotechnology <u>paused enrollment for a study</u> testing their experimental COVID-19 antibody therapy.